FILTER
FILTERED INTERVIEW RESULTS
Rajiv Anand
FOUNDER AND CEO, QUARTIC.AI
"Digital transformation helps accelerate drug pipelines by reducing workload and increasing efficiency."
James Stephens and Darrell Tweidt
CLIENT SERVICES MANAGERS, PREMIER DRILLING CO.
"Experienced drillers who understand the local terrain are crucial for success."
Himanshu Gadgil
CEO, ENZENE BIOSCIENCES
"From an innovation point of view, breaking the US$40/gram cost barrier for production of mAbs is a key objective this year."
George Bee
PRESIDENT AND CEO, U.S. GOLD CORP
"Our permitted status positions us favorably to capitalize on these market conditions, with the lower cost CK project production being attractive, particularly as established gold producers struggle to maintain production levels."
Mike Radomsky
PRESIDENT, CMC PHARMACEUTICALS
"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."
Andrea Confetti and Roberto Fanelli
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS
"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."
Chris Dougherty
PRESIDENT AND CHAIRMAN, NORDMIN ENGINEERING
"Given the industry’s challenges, including cost increases and procurement delays, working as a team is essential."
Charles Kocsis
PROFESSOR & FORMER DEPARTMENT CHAIR - DEPARTMENT OF MINING ENGINEERING, THE UNIVERSITY OF UTAH
"Our focus is on advancing innovations in mine automation, efficient ventilation, mine design, and cooling systems to boost productivity and prioritize worker safety."
Donna LaVoie
FOUNDER AND CEO, LAVOIEHEALTHSCIENCE
"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."
Debbie Hart
PRESIDENT AND CEO, BIONJ
"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
USA Mining 2025-26 - Pre-release
USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.
USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
